GlobeNewswire by notified

Consolidated Unaudited Interim Report of AS PRFoods for the 1nd quarter and 3 months of 2021/2022 financial year



Q1 had many things we can be satisfied with- our sales grew by 11.5% and group net loss decreased by 50%. Unfortunately, there are many things, that unearthed massive management mistakes in Finnish unit. All PRFoods current problems stem from management mistakes made in 2020-2021. As of toda, we have completed 100% the change of management and key people in Finland, that we started in summer and decision to close lossmaking Kokkola factory. These steps build base for renewal of profitability in 2022.

Corona crises speed up the unearthing of weaknesses in Finnish unit, and unfortunately the previous management did not want to acknowledge their mistakes or correct them. The proof that we are on right track with right people who joined us in fall this year, is the fact as of October we back to being profitable also in Finland: Heimon Kala Oy October EBITDA was 28 thousand euros and better by 270 thousand euros on YoY basis. Finnish unit caused liquidity crisis, which we are correcting with increased performance of our farming unit and cashflow released from biomass harvesting.

Thanks to the changes made to product portfolio and production by new Finnish management, we are out of all non-profitable products in Finland and have secured price and sales increases for next year in all categories. Considering the turbulent times in Finland, we aim to provide investors with regular updates from this unit.

Very well performed our UK unit, who despite some one-offs, fulfilled its EBITDA target in the sum of 172 thousand euros. Estonian EBITDA was still in minus by 150 thousand euros in Q1 due to loss-making Finnish sales.

The decline in Finnish management continued in summer, where instead of cutting loss-making production, they increased it, resulting in 880 thousand euros EBITDA loss.

Fish farming is making very good results in current quarter thanks to increased harvest volume and prices. Fish farming could even post a better EBITDA, but we delayed our Swedish harvest until Q1 2022 due to smaller biomass increase in hot summer. Considering that fresh fish prices are higher in winter, this decision has positive economic impact. At the same time this will decrease our cash flow from biomass in current quarter by 1.5 million euros, which will be deferred until Q1 2022.

We have followed our previously announced plan to emerge from this crisis:

  1. Decrease our bank loans: cash flow from financing was -1.5 million euros in Q1
  2. Restructure totally Finnish unit, including selling possibly or closing units or closing loss making units. Eliminating form Finnish sales all low margin products: target achieved by end of 2021.
  3. Increas retail sales in UK, EU and other domestic markets: target achieved in all markets, except Finland.
  4. Group’s strategic focus is on fish farming, as area that has been constantly profitable. Group’s target ist o achieve 10 thousand tons of biomass by 2023, which should give group sales of 40-50 million euros: Swedish farms should contribute already additional 1.500-1.700 tons of biomass by fall 2022.

Group’s financial position is not easy. At the same time, we must remember that 11 million euros bonds have been issued solely for refinancing of John Ross Jr. Acquisition and John Ross Jr results have not been impacted so severly, their operational cash flow is very strong and they pay regularly dividends to parent company, therefore we find their leverage to be acceptable.

Fish farming requires long term capital for fish feed and this is under works.

Last year we were forced to reduce significantly working capital financing through banks, which put strain on company’s finances. We have reduced significantly working capital needs in operations, also through lower inventory. Most important is to restore profitability in the environment of lower sales and restructure loss-making business units.

Having cut our teeth now for second year in corona crisis, we know that it is not sustainable to rely on outside help and all tough decisions need to be taken sooner than later. For our advantage the fish market has started much stronger this year and is more predictable and demand for our products is growing. The only objective of new financial year is profit and everything that blocks our road to profitabilty must be eliminated.



mln EUR3Q 20212Q 20211Q 20214Q 20203Q 20202Q 20201Q 20204Q 2019
Gross profit0.
EBITDA from operations-0.8-1.0-0.50.6-0.3-
Net profit (-loss) -0.7-1.7-1.8-0.2-1.4-1.3-1.70.5
Gross margin 5.4%2.1%6.6%14.9%9.4%4.4%10.8%17.0%
Operational EBITDA margin-5.5%-7.0%-3.5%3.4%-2.6%-0.9%0.1%8.4%
EBITDA margin-0.1%-4.8%-5.3%4.1%-3.8%-0.5%-4.6%5.3%
EBIT margin-4.7%-9.3%-9.9%0.2%-8.8%-6.4%-7.8%2.9%
EBT margin-4.6%-10.8%-12.5%-0.6%-11.3%-8.3%-9.8%2.2%
Net margin -5.2%-11.6%-12.5%-1.2%-11.3%-8.4%-9.2%2.0%
Operating expense ratio16.3%15.4%15.6%15.6%18.2%14.0%14.3%12.5%


mln EUR30.09.202130.06.202131.03.202131.12.202030.09.202030.06.202031.03.2020
Net debt24.220.921.421.921.520.717.0
Working capital-2.6-2.9-5.0-3.9-4.4-4.0-2.5
Liquidity ratio0.9x0.9x0.8x0.8x0.8x0.8x0.9x
Equity ratio 26.7%28.6%32.4%32.4%32.3%34.7%37.9%
Gearing ratio61.8%56.9%54.9%54.0%53.7%51.1%44.0%
Debt to total assets0.7x0.7x0.7x0.7x0.7x0.7x0.6x
Net debt to EBITDA op-14.3x-16.9x-55.3x160.0x12.8x7.5x5.3x

Consolidated Statement of Financial Position

Thousand euros30.09.202130.09.202030.06.2021
Cash and cash equivalents7481.0912.500
Receivables and prepayments3.2313.2323.512
Biological assets7.7465.4234.795
Total current assets17.36318.49216.498
Deferred income tax385438
Long-term financial investments305232302
Tangible fixed assets14.89716.00615.300
Intangible assets23.36822.60623.460
Total non-current assets38.60838.89839.100
TOTAL ASSETS55.97157.39055.598
Loans and borrowings6.52110.3227.325
Government grants207212207
Total current liabilities19.94722.91919.656
Loans and borrowings18.41112.26117.561
Deferred tax liabilities1.9961.9341.861
Government grants695833746
Total non-current liabilities21.10215.92820.168
TOTAL LIABILITIES41.04938.84739.824
Share capital7.7377.7377.737
Share premium14.00714.19814.007
Treasury shares-390-390-390
Statutory capital reserve515151
Currency translation reserve447-397559
Retained profit (-loss)-7.641-3.056-6.723
Equity attributable to parent14.21118.14315.241
Non-controlling interest711400533
TOTAL EQUITY14.92218.54315.774

Consolidated Statement of Profit or Loss And Other Comprehensive Income

Thousand euros3m 2021/20223m 2020/2021
Cost of goods sold-13.433-11.537
Gross profit7741.200
Operating expenses-2.309-2.322
Selling and distribution expenses-1.581-1.558
Administrative expenses-728-764
Other income / expense5191
Fair value adjustment on biological assets820-94
Operating profit (loss)-664-1.125
Financial income/-expenses16-309
Profit (loss) before tax-648-1.434
Income tax-92-4
Net profit (loss) for the period-740-1.438
Net profit (loss) attributable to:
Owners of the company-918-1.402
Non-controlling interests178-36
Total net profit (loss)-740-1.438
Other omprehensive income (loss) that may subsequently be classified to profit or loss:
Foreign currency translation differences-112-31
Total comprehensive income (expense)-852-1.469
Total comprehensive income (expense) attributable to:
Owners of the Company-842-1.433
Non-controlling interests-10-36
Total comprehensive income (expense) for the period-852-1.469
Profit (loss) per share (EUR)-0.02-0.04
Diluted profit (loss) per share (EUR)-0.02-0.04

Indrek Kasela

AS PRFoods

Member of the Management Board

Phone:+372 452 1470


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alation Welcomes Tim Harford OBE as Keynote Speaker at revAlation in London18.8.2022 09:00:00 CEST | Press release

World renowned behavioural economist joins The Very Group CDO to keynote Alation’s industry conference LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Alation Inc., the leader inenterprise data intelligence solutions, today announced that revAlation, its flagship industry conference for data professionals across EMEA, will take place on 4th October and 5th October at County Hall, London. The two-day event will feature data networking opportunities, data training, and keynotes from award winning economist, journalist, and broadcaster Tim Harford, and Chief Data Officer of The Very Group, Steve Pimblett. Tim Harford is a bestselling author of books about economics and data, and the writer of the award-winning Financial Times column, The Undercover Economist. Harford will keynote the event and discuss how to use data and economics in everyday life. Steve Pimblett is the Chief Data Officer at leading UK and Ireland online retailer, The Very Group. Pimblett is an experienced data professional, ha

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)18.8.2022 08:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 August 2022 at 9:30 am Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly or indirectly by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 16 August 2022 below five (5) per cent of Sampo plc’s total voting rights. Sampo's share capital comprises 533,261,351 shares, of which 533,061,351 are A shares and 200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 534,061,351. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B)Resultin

Systemair's Interim Report for the first quarter will be presented on August 2518.8.2022 08:00:00 CEST | Press release

Press Release, 18 August 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q1 for the financial year 2022/23 will be published at 13:00 CET on August 25, 2022. A telephone conference will be held at 13:30 CET on August 25, 2022. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. In order to participate in the telephone conference: Call 010-884 8016 alternative international call +44 20 3936 2999 and enter code 539199 minutes before start. The presentation will be published on For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, Systemair in brief Systemair is a leading ventilation company with operations in 52 countries in Europe, North America, the Middle East, Asia, Australia and Africa. The Company had sales of SEK 9.6 billion in the 2021/22 financial year and today employs approximately 6,700

Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review18.8.2022 08:00:00 CEST | Press release

The TENDU interim safety results from nine patients show no safety concernsTrial extended to enroll up to three additional patients at the highest dose levelTENDU designed to evaluate the Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer Oslo, 18August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level. The Drug Safety Monitoring Board, a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns in any of the three dose cohorts. A total of nine patients have now been treated; three at each dose level (40 mcg, 400 mcg and 960 mcg). Ultimovacs plans to enroll up to three additional patients at the highest dose level (960 mcg) pro

Systemairs rapport för det första kvartalet presenteras den 25 augusti18.8.2022 08:00:00 CEST | Pressemelding

Pressmeddelande 18 augusti 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) delårsrapport Q1 för räkenskapsåret 2022/23 kommer att offentliggöras kl. 13:00 CET den 25 augusti 2022. En telefonkonferens arrangeras kl. 13:30 CET den 25 augusti 2022. Rapporten presenteras av Roland Kasper, CEO, samt Anders Ulff, CFO. För att delta i telefonkonferensen: Ring 010-884 8016 alt. internationellt +44 20 3936 2999 och uppge kod 539199 minuter före start. Presentationen publiceras på För ytterligare information kontakta: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, Systemair i korthet Systemair är ett ledande ventilationsföretag med verksamhet i 52 länder i Europa, Nordamerika, Mellanöstern, Asien, Australien och Afrika. Bolaget omsatte 9,6 miljarder kronor räkenskapsåret 2021/22 och har idag cirka 6 700 anställda. Sedan grundandet av Systemair 1974 har bolaget uppvisat positiva rör